Publications for Anders Olsson
Co-author map based on ISI articles 2007-

Publications mentioned in social media 148 times*

Keywords

trial treatment statin simvastatin serum risk prevention patients mg lysosomal lipoprotein ldl events disease death coronary cholesterol cardiovascular baseline atorvastatin

Journal Articles

Barbara Sjouke, Gisle Langslet, Richard Ceska, Stephen J. Nicholls, Steven E. Nissen, Maria Ohlander, Paul W. Ladenson, Anders Olsson, G. Kees Hovingh and John J. P. Kastelein
  Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study
 
Altmetric usage: 7

  LANCET DIABETES and ENDOCRINOLOGY, 2014, 2(6), 455-463.

Michael V. Holmes, Tabassome Simon, Holly J Exeter, Lasse Folkersen, Folkert W. Asselbergs, Montse Guardiola, Jackie A. Cooper, Jutta Palmen, Jaroslav A. Hubacek, Kathryn F. Carruthers, Benjamin D. Horne, Kimberly D. Brunisholz, Jessica L. Mega, Erik P A Van Iperen, Mingyao Li, Maarten Leusink, Stella Trompet, Jeffrey J W. Verschuren, G Kees Hovingh, Abbas Dehghan, Christopher P. Nelson, Salma Kotti, Nicolas Danchin, Markus Scholz, Christiane Haase L., Dietrich Rothenbacher, Daniel I. Swerdlow, Karoline B. Kuchenbaecker, Eleonora Staines-Urias, Anuj Goel, Ferdinand van t Hooft, Karl Gertow, Ulf de Faire, Andrie G. Panayiotou, Elena Tremoli, Damiano Baldassarre, Fabrizio Veglia, Lesca M. Holdt, Frank Beutner, Ron T. Gansevoort, Gerjan J. Navis, Irene Mateo Leach, Lutz P. Breitling, Hermann Brenner, Joachim Thiery, Dhayana Dallmeier, Anders Franco-Cereceda, Jolanda M A. Boer, Jeffrey W. Stephens, Marten H. Hofker, Alain Tedgui, Albert Hofman, Andre G. Uitterlinden, Vera Adamkova, Jan Pitha, Charlotte N. Onland-Moret, Maarten J. Cramer, Hendrik M. Nathoe, Wilko Spiering, Olaf H. Klungel, Meena Kumari, Peter H. Whincup, David A. Morrow, Peter S. Braund, Alistair S. Hall, Anders G. Olsson, Pieter A. Doevendans, Mieke D. Trip, Martin D. Tobin, Anders Hamsten, Hugh Watkins, Wolfgang Koenig, Andrew N. Nicolaides, Daniel Teupser, Ian N M Day, John F Carlquist, Tom R. Gaunt, Ian Ford, Naveed Sattar, Sotirios Tsimikas, Gregory G. Schwartz, Debbie A. Lawlor, Richard W. Morris, Manjinder S. Sandhu, Rudolf Poledne, Anke H. Maitland-van der Zee, Kay-Tee Khaw, Brendan J. Keating, Pim van der Harst, Jackie F. Price, Shamir R. Mehta, Salim Yusuf, Jaqueline C M Witteman, Oscar H. Franco, Wouter J. Jukema, Peter de Knijff, Anne Tybjaerg-Hansen, Daniel J. Rader, Martin Farrall, Nilesh J. Samani, Mika Kivimaki, Keith A A. Fox, Steve E. Humphries, Jeffrey L. Anderson, Matthijs S. Boekholdt, Tom M. Palmer, Per Eriksson, Guillaume Pare, Aroon D. Hingorani, Marc S. Sabatine, Ziad Mallat, Juan P. Casas and Philippa J. Talmud
  Secretory Phospholipase A(2)-IIA and Cardiovascular Disease
 
Altmetric usage: 1

  Journal of the American College of Cardiology, 2013, 62(21), 1966-1976.
 Web of Science® Times Cited: 10

Matti J. Tikkanen, Rana Fayyad, Ole Faergeman, Anders Olsson, Chuan-Chuan Wun, Rachel Laskey, John J. Kastelein, Ingar Holme and Terje R. Pedersen
  Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels
 
Altmetric usage: 1

  International Journal of Cardiology, 2013, 168(4), 3846-3852.
 Web of Science® Times Cited: 7

Payman Zamani, Gregory G. Schwartz, Anders Olsson, Nader Rifai, Weihang Bao, Peter Libby, Peter Ganz and Scott Kinlay
  Inflammatory Biomarkers, Death, and Recurrent Nonfatal Coronary Events After an Acute Coronary Syndrome in the MIRACL Study
 
Altmetric usage: 2

  Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2013, 2(1), .
 Web of Science® Times Cited: 4

David Sullivan, Anders Olsson, Rob Scott, Jae B Kim, Allen Xue, Val Gebski, Scott M Wasserman and Evan A Stein
  Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients The GAUSS Randomized Trial
 
Altmetric usage: 11

  Journal of the American Medical Association (JAMA), 2012, 308(23), 2497-2506.
 Web of Science® Times Cited: 68

Gregory G Schwartz, Anders Olsson, Markus Abt, Christie M Ballantyne, Philip J Barter, Jochen Brumm, Bernard R Chaitman, Ingar M Holme, David Kallend, Lawrence A Leiter, Eran Leitersdorf, John J V McMurray, Hardi Mundl, Stephen J Nicholls, Prediman K Shah, Jean-Claude Tardif and R Scott Wright
  Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
 
Altmetric usage: 121

  New England Journal of Medicine, 2012, 367(22), 2089-2099.
 Web of Science® Times Cited: 193

Robert L. Ohsfeldt, Anders G Olsson, Marie M. Jensen, Sanjay K. Gandhi and Thomas Paulsson
  Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the Jupiter trial
  Journal of Media Economics, 2012, 15(1), 125-133.

Sanya K. Gandhi, Marie M. Jensen, Kathleen M. Fox, Lee Smolen, Anders Olsson and Thomas Paulsson
  Cost-effectiveness of resuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events
  ClinicoEconomics and Outcomes Research, 2012, 4, 1-11.
   Fulltext  PDF  

Darbie L Maccubbin, Fabian Chen, Jennifer Weimer Anderson, Waheeda Sirah, Christine McCrary Sisk, Uma Kher, Anders Olsson, Harold E Bays and Yale B Mitchel
  Effectiveness and Safety of Laropiprant on Niacin-Induced Flushing
 
Altmetric usage: 1

  American Journal of Cardiology, 2012, 110(6), 817-822.
 Web of Science® Times Cited: 6

Sung Kee Ryu, Ziad Mallat, Joelle Benessiano, Alain Tedgui, Anders Olsson, Weihang Bao, Gregory G Schwartz and Sotirios Tsimikas
  Phospholipase A(2) Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes
  Circulation, 2012, 125(6), 757-U71.
 Web of Science® Times Cited: 19

Anders G. Olsson
  Diskussionen om vad som ska vara målet för lipidsänkning fortsätter: Expertrådet - en stoppkloss för modern kardiovaskulär prevention: [The discussion on target goals in lipid reduction is still going on. The expert committee - a block for current cardiovascular prevention]
  Läkartidningen, 2011, 108(47), 2443.

Anders G. Olsson
  Målvärden för LDL-kolesterol har satts ur spel. Kolesterolet bör sänkas maximalt vid hög kardiovaskulär risk: [Target levels for LDL cholesterol are put out of the running. Cholesterol should be lowered maximally in high cardiovascular risk]
  Läkartidningen, 2011, 108(22-23), 1240-1243.

Anders G Olsson
  Statin efter intracerebral blödning bör ifrågasättas: Subgruppsanalyser visar på ökad risk för ny blödning
  Läkartidningen, 2011, 108(24-25), 1297-1298.

Anders Olsson, Christina Lindahl, Ingar Holme, Rana Fayyad, Ole Faergeman, John J P Kastelein, Matti J Tikkanen, Mogens Lytken Larsen and Terje R Pedersen
  LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study
 
Altmetric usage: 1

  EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION and REHABILITATION, 2011, 18(2), 262-269.
 Web of Science® Times Cited: 3

Anders G Olsson
  HDL and LDL as therapeutic targets for cardiovascular disease prevention: The possible role of niacin
  NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2010, 20(8), 553-557.
 Web of Science® Times Cited: 3

Anders Olsson, Finn Bengtsson, A. Rosengren and P. Tornvall
  Patienten framför allt!
  Läkartidningen, 2010, 107(24), 1639.

Terje R Pedersen, Nilo B Cater, Ole Faergeman, John J P Kastelein, Anders Olsson, Matti J Tikkanen, Ingar Holme, Mogens Lytken Larsen, Christina Lindahl and Michael Szarek
  Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial)
  AMERICAN JOURNAL OF CARDIOLOGY, 2010, 106(3), 354-359.
 Web of Science® Times Cited: 13

Anders Olsson
  Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease
  Expert Opinion on Pharmacotherapy, 2010, 11(10), 1715-1726.
 Web of Science® Times Cited: 8

Anders Olsson, Finn Bengtsson, A. Rosengren and P. Tornvall
  Kolesterolhypotesen står sig
  Läkartidningen, 2010, 107(12), 831-836.

I Holme, R Fayyad, O Faergeman, J J P Kastelein, Anders Olsson, M J Tikkanen, M L Larsen, C Lindahl, H Holdaas and T R Pedersen
  Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial
  JOURNAL OF INTERNAL MEDICINE, 2010, 267(6), 567-575.
 Web of Science® Times Cited: 7

Paul W Ladenson, Jens D Kristensen, E Chester Ridgway, Anders Olsson, Bo Carlsson, Irwin Klein, John D Baxter and Bo Angelin
  Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia
  NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362(10), 906-916.
 Web of Science® Times Cited: 120

Anders G Olsson
  JUPITER-studien lyfter fram primärprevention
  Läkartidningen, 2009, 106(23), 1577.

Anders G Olsson
  Livsstilsförändring och läkemedel kompletterar varandra
  Läkartidningen, 2009, 106(34), 2069.

Anders G Olsson
  Slutrunda om statiner: Faktum kvarstår att 80 mg simvastatin dagligen ger hög myopatirisk
  Läkartidningen, 2009, 106(43), 2783-4; author reply 2784.

Anders Olsson
  Faktum kvarstår att 80 mg simvastatin dagligen ger hög myopatirisk
  Läkartidningen, 2009, 106(43), 2783.

Anders Olsson
  Varning för simvastatin 80 mg!
  Läkartidningen, 2009, 106(40), 2549-2550.

Gregory G Schwartz, Anders Olsson, Christie M Ballantyne, Phillip J Barter, Ingar M Holme, David Kallend, Lawrence A Leiter, Eran Leitersdorf, John J V McMurray, Prediman K Shah, Jean-Claude Tardif, Bernard R Chaitman, Regina Duttlinger-Maddux and John Mathieson
  Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
 
Altmetric usage: 1

  American Heart Journal, 2009, 158(6), 896-U34.
 Web of Science® Times Cited: 98

Matti J Tikkanen, Michael Szarek, Rana Fayyad, Ingar Holme, Nilo B Cater, Ole Faergeman, John J P Kastelein, Anders Olsson, Mogens Lytken Larsen, Christina Lindahl and Terje R Pedersen
  Total Cardiovascular Disease Burden: Comparing Intensive With Moderate Statin Therapy Insights From the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) Trial
  Journal of the American College of Cardiology, 2009, 54(25), 2353-2357.
 Web of Science® Times Cited: 26

Scott Kinlay, Gregory G Schwartz, Anders Olsson, Nader Rifai, Weihang Bao, Peter Libby and Peter Ganz
  Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study
  Atherosclerosis, 2009, 206(2), 551-555.
 Web of Science® Times Cited: 5

Anders Olsson and Peter M. Nilsson
  "The lower LDL cholesterol levels, the better" still valid. Negative/neutral conclusions of three studies on statins do not change the clinical practice ["Ju lägre LDL-kolesterol, desto bättre" gäller fortsatt Negativa/neutrala slutsatser av tre statinstudier ändrar inte klinisk praxis.]
  Läkartidningen, 2009, 106(12), 854-857.

Anders Olsson
  JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor [JUPITER kan ge paradigmskifte i prevention av hjärt-kärlsjukdom. Fokus på inflammation som riskfaktor.]
  Läkartidningen, 2009, 106(21-22), 1471-1475.

Ole Faergeman, Ingar Holme, Rana Fayyad, Sonal Bhatia, Scott M Grundy, John J P Kastelein, John C LaRosa, Mogens Lytken Larsen, Christina Lindahl, Anders G Olsson, Matti J Tikkanen, David D Waters and Terje R Pedersen
  Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease
 
Altmetric usage: 1

  AMERICAN JOURNAL OF CARDIOLOGY, 2009, 104(4), 459-463.
 Web of Science® Times Cited: 33

Ingar Holme, Timo E Strandberg, Ole Faergeman, John J P Kastelein, Anders Olsson, Matti J Tikkanen, Mogens Lytken Larsen, Christina Lindahl and Terje R Pedersen
  Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL)
  ATHEROSCLEROSIS, 2009, 205(2), 522-527.
 Web of Science® Times Cited: 6

Anders G Olsson
  Lipid lowering and aortic valve disease
  CURRENT ATHEROSCLEROSIS REPORTS, 2009, 11(5), 377-383.
 Web of Science® Times Cited: 1

Ingar Holme, Michael Szarek, Nilo B Cater, Ole Faergeman, John J P Kastelein, Anders Olsson, Matti J Tikkanen, Mogens Lytken Larsen, Christina Lindahl and Terje R Pedersen
  Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study
  EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION and REHABILITATION, 2009, 16(3), 315-320.
 Web of Science® Times Cited: 8

Alexander E Fraley, Gregory G Schwartz, Anders Olsson, Scott Kinlay, Michael Szarek, Nader Rifai, Peter Libby, Peter Ganz, Joseph L Witztum and Sotirios Tsimikas
  Relationship of Oxidized Phospholipids and Biomarkers of Oxidized Low- Density Lipoprotein With Cardiovascular Risk Factors, Inflammatory Biomarkers, and Effect of Statin Therapy in Patients With Acute Coronary Syndromes Results From the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) Trial
  JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53(23), 2186-2196.
 Web of Science® Times Cited: 31

Timo E Strandberg, Ingar Holme, Ole Faergeman, John J P Kastelein, Christina Lindahl, Mogens Lytken Larsen, Anders Olsson, Terje R Pedersen and Matti J Tikkanen
  Comparative Effect of Atorvastatin (80 mg) Versus Simvastatin (20 to 40 mg) in Preventing Hospitalizations for Heart Failure in Patients With Previous Myocardial Infarction
  AMERICAN JOURNAL OF CARDIOLOGY, 2009, 103(10), 1381-1385.
 Web of Science® Times Cited: 8

M.J. Tikkanen, I. Holme, N.B. Cater, M. Szarek, O. Faergeman, J.J.P. Kastelein, Anders Olsson, M.L. Larsen, C. Lindahl and T.R. Pedersen
  Comparison of Efficacy and Safety of Atorvastatin (80 mg) to Simvastatin (20 to 40 mg) in Patients Aged less than65 Versus =65 Years With Coronary Heart Disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] Study)
  American Journal of Cardiology, 2009, 103(5), 577-582.
 Web of Science® Times Cited: 22

Simona Ioana Chisalita, Torbjörn Lindström, Pär Eson Jennersjö, Johan Paulsson, Gunilla Westermark, Anders Olsson and Hans Arnqvist
  Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control
  Acta Diabetologica, 2009, 46(1), 35-42.
   Fulltext  PDF  
 Web of Science® Times Cited: 4

Anders Olsson
  Is high HDL cholesterol always good?
  ANNALS OF MEDICINE, 2009, 41(1), 11-18.
 Web of Science® Times Cited: 9

Anders Olsson
  Nationella riktlinjer för hjärtsjukvård 2008:  Lägesbeskrivning eller instrument för förändring?
  Läkartidningen, 2008, , 17-18.

Milita Crisby and Anders Olsson
  Statin i hög dos vid ischemisk stroke minskar risken för ny stroke
  Läkartidningen, 2008, 105(48-49), 3541-3543.

I. Holme, N.B. Cater, O. Faergeman, J.J.P. Kastelein, Anders G. Olsson, M.J. Tikkanen, Larsen M. Lytken, C. Lindahl and T.R. Pedersen
  Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL)
  Annals of Medicine, 2008, 40(6), 456-464.
 Web of Science® Times Cited: 20

S. Kinlay, G.G. Schwartz, Anders G. Olsson, N. Rifai, M. Szarek, D.D. Waters, P. Libby and P. Ganz
  Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study
  Arteriosclerosis, Thrombosis and Vascular Biology, 2008, 28(1), 142-147.
 Web of Science® Times Cited: 37

der Steeg W.A. van, I. Holme, S.M. Boekholdt, M.L. Larsen, C. Lindahl, E.S.G. Stroes, M.J. Tikkanen, N.J. Wareham, O. Faergeman, Anders G Olsson, T.R. Pedersen, K.-T. Khaw and J.J.P. Kastelein
  High-Density Lipoprotein Cholesterol, High-Density Lipoprotein Particle Size, and Apolipoprotein A-I: Significance for Cardiovascular Risk. The IDEAL and EPIC-Norfolk Studies
  Journal of the American College of Cardiology, 2008, 51(6), 634-642.
 Web of Science® Times Cited: 138

D. Maccubbin, H.E. Bays, Anders Olsson, V. Elinoff, A. Elis, Y. Mitchel, W. Sirah, A. Betteridge, R. Reyes, Q. Yu, O. Kuznetsova, C.M. Sisk, R.C. Pasternak and J.F. Paolini
  Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia
  International journal of clinical practice (Esher), 2008, 62(12), 1959-1970.
 Web of Science® Times Cited: 65

John J. P. Kastelein, Wim A. van der Steeg, Ingar Holme, Michael Gaffney, Nilo B. Cater, Philip Barter, Prakash Deedwania, Anders Olsson, S. Matthijs Boekholdt, David A. Demicco, Michael Szarek, John C. LaRosa, Terje R. Pedersen and S Grundy
  Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
  Circulation, 2008, 117(23), 3002-3009.
 Web of Science® Times Cited: 179

Anders Olsson
  Commentary: Will CETP Inhibition Survive the Demise of Torcetrapib?: in CURRENT ATHEROSCLEROSIS REPORTS, ISSN 1523-3804, vol 10, issue 2, pp 97-99
  Current Atherosclerosis Reports, 2008, 10(2), 97-99.

J. Karppi, T.H. Rissanen, K. Nyyssonen, J. Kaikkonen, Anders G. Olsson, S. Voutilainen and J.T. Salonen
  Effects of astaxanthin supplementation on lipid peroxidation
  International Journal for Vitamin and Nutrition Research, 2007, 77(1), .
 Web of Science® Times Cited: 20

M.J. Tikkanen, G. Jackson, T. Tammela, G. Assmann, A. Palomaki, M. Kupari and Anders Olsson
  Erectile dysfunction as a risk factor for coronary heart disease: Implications for prevention
  International journal of clinical practice (Esher), 2007, 61(2), 265-268.
 Web of Science® Times Cited: 16

Andes G. Olsson, G.G. Schwartz, M. Szarek, D. Luo and M.J. Jamieson
  Effects of High-Dose Atorvastatin in Patients =65 Years of Age With Acute Coronary Syndrome (from the Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering [MIRACL] Study)
  American Journal of Cardiology, 2007, 99(5), 632-635.
 Web of Science® Times Cited: 30

Peter Lindgren, Jennifer Graff, Anders Olsson, Terje J Pedersen and Bengt Jönsson
  Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin
  European Heart Journal, 2007, 28(12), 1448-1453.
 Web of Science® Times Cited: 27

Johnny Nijm, Margareta Kristenson, Anders G. Olsson and Lena Jonasson
  Impaired cortisol response to acute stressors in patients with coronary disease: Implications for inflammatory activity
 
Altmetric usage: 1

  Journal of Internal Medicine, 2007, 262(3), 375-384.
 Web of Science® Times Cited: 29

T.R. Pedersen, O. Faergeman, J.J.P. Kastelein, Anders Olsson, M.J. Tikkanen, I. Holme, M.L. Larsen and F.S. Bendiksen
  High-dose statins and the IDEAL study: Reply
  Journal of the American Medical Association (JAMA), 2006, 295(21), 2478-2479.

Anders Olsson
  The lower the better? Experiences from cardiovascular disease and stroke prevention
  Acta Neurologica Scandinavica, 2006, 114(SUPPL. 185), 58-62.

Anders G. Olsson
  Expanding options with a wider range of rosuvastatin doses
  Clinical Therapeutics, 2006, 28(11), 1747-1763.
 Web of Science® Times Cited: 3

Anders Olsson
  Are lower levels of low-density lipoprotein cholesterol beneficial? A review of recent data
  Current Atherosclerosis Reports, 2006, 8(5), 382-389.

Anders Olsson
  PPAR agonists do not come up to expectations. Hope about the preventive effect in type 2 diabetes has comte to nought
  Läkartidningen, 2006, 103(35), 2454-2455.

Gunilla Hollman, Anders Olsson and Anna-Christina Ek
  Disease knowledge and adherence to treatment in patients with familial hypercholesterolemia
  Journal of Cardiovascular Nursing, 2006, 21(2), 103-108.
 Web of Science® Times Cited: 6

Anders Olsson
  Lägre LDL-kolesterol är bättre! Sikta på 2mmol/l i sekundärpreventiv behandling
  Läkartidningen, 2006, 103, 22-23.

T R Pedersen, O Faergeman, JJP Kastelein, Anders Olsson, MJ Tikkanen, I Holme, ML Larsen, FS Bendiksen, C Lindahl, M Szarek and J Tsai
  High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction - The IDEAL study: A randomized controlled trial
  Journal of the American Medical Association (JAMA), 2005, 294(19), 2437-2445.
 Web of Science® Times Cited: 688

Bo Ziedén and Anders Olsson
  The role of statins in the prevention of ischemic stroke
  Current Atherosclerosis Reports, 2005, 7(5), 364-368.

G.G. Schwartz, Anders Olsson, M. Szarek and W.J. Sasiela
  Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: An analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial
  Diabetes Care, 2005, 28(10), 2508-2513.
 Web of Science® Times Cited: 41

H. Holdaas, B. Fellstrom, E. Cole, G. Nyberg, Anders G. Olsson, T.R. Pedersen, S. Madsen, C. Gronhagen-Riska, H.-H. Neumayer, B. Maes, P. Ambuhl, A. Hartmann, B. Staffler and A.G. Jardine
  Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT extension study
  American Journal of Transplantation, 2005, 5(12), 2929-2936.
 Web of Science® Times Cited: 131

Sotirios Tsimikas, Joseph L Witztum, Elisabeth R Miller, William J Sasiela, Michael Szarek, Anders Olsson and Gregory G Schwartz
  Letter regarding article by Tsimikas et al, - "High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial" - Response
  Acta Obstetricia et Gynecologica Scandinavica, 2005, 111(18), e284-e285.

AG Jardine, B Fellstrom, JO Logan, E Cole, G Nyberg, C Gronhagen-Riska, S Madsen, HH Neumayer, B Maes, P Ambuhl, Anders Olsson, T Pedersen and H Holdaas
  Cardiovascular risk and renal transplantation: Post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) study
  American Journal of Kidney Diseases, 2005, 46(3), 529-536.
 Web of Science® Times Cited: 53

B. Fellstrom, H. Holdaas, A.G. Jardine, G. Nyberg, C. Gronhagen-Riska, S. Madsen, H.-H. Neumayer, E. Cole, B. Maes, P. Ambuhl, Anders Olsson, B. Staffler and T.R. Pedersen
  Risk factors for reaching renal endpoints in the Assessment of Lescol in Renal Transplantation (ALERT) trial
  Transplantation, 2005, 79(2), 205-212.
 Web of Science® Times Cited: 38

Margareta Kristenson, Anders Olsson and Zita Kucinskiene
  Good self-rated health is related to psychosocial resources and a strong cortisol response to acute stress: The LiVicordia study of middle-aged men
  International Journal of Behavioral Medicine, 2005, 12(3), 153-160.
 Web of Science® Times Cited: 18

Mark Hirsch, John O´Donnell and Anders Olsson
  Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals
  International Journal of Cardiology, 2005, 104(3), 251-256.
 Web of Science® Times Cited: 8

Gerd Assman, Paul Cullen, Jean-Charles Fruchart, Heiner Greten, Marek Naruszewicz, Anders Olsson, Rudolfo Paoletti, Walter Riesen, Monika Stoll, Matti Tikkanen and Arnold Von Eckardstein
  Implications of emerging risk factors for therapeutic intervention
  NMCD. Nutrition Metabolism and Cardiovascular Diseases, 2005, 15(5), 373-381.
 Web of Science® Times Cited: 12

Anders Olsson
  Kontrollerade kliniska prövningar ger bästa svaret
  Läkartidningen, 2005, 102, 2584-2587.

Gregory G Schwartz and Anders Olsson
  The case for intensive statin therapy after acute coronary syndromes
  American Journal of Cardiology, 2005, 96( 5 SUPPL.), .
 Web of Science® Times Cited: 16

Anders Olsson
  TNT-studien ger skjuts i debatten om högdos statiner
  Läkartidningen, 2005, 102, 18-19.

Anders Olsson, G Schwartz, M Szarek, W Sasiela, M Ezekowitz, P Ganz, M Oliver, D Waters and A Zeiher
  High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: Results from the MIRACL trial
  European Heart Journal, 2005, 26(9), 890-896.
 Web of Science® Times Cited: 79

Anders Olsson
  Risk factors for reaching renal endpoints in the assessment of lescol in renal transplantation (ALERT) trial
  Transplantation, 2005, 792, 205-212.
 Web of Science® Times Cited: 38

Anders Olsson
  A to Z
  Information från Läkemedelsverket, 2005, 1, 16-17.

Anders Olsson
  Prove-it
  Information från Läkemedelsverket, 2005, 1, 14-15.

Anders Olsson
  Det metabola syndromet och dess konsekvenser
  Incitament, 2005, 1, 25-27.

Johnny Nijm, Anders Wikby, Andrea Tompa, Anders G Olsson and Lena Jonasson
  Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease
  American Journal of Cardiology, 2005, 95(4), 452-456.
 Web of Science® Times Cited: 64

B Fellstrom, H Holdaas, AG Jardine, I Holme, G Nyberg, P Fauchald, C Gronhagen-Riska, S Madsen, HH Neumayer, E Cole, B Maes, P Ambuhl, Anders Olsson, A Hartmann, JO Logan and TR Pedersen
  Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial
  Kidney International, 2004, 66(4), 1549-1555.
 Web of Science® Times Cited: 63

T.R. Pedersen, O. Faergeman, J.J.P. Kastelein, Anders Olsson, M.J. Tikkanen, I. Holme, M.L. Larsen, F.S. Bendiksen, C. Lindahl and G. Palmer
  Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study
  American Journal of Cardiology, 2004, 94(6), 720-724.
 Web of Science® Times Cited: 33

Anders Olsson, Roman Casciano, Lee Stern and Per Svengren
  A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden
  International Journal of Cardiology, 2004, 96(1), 51-57.
 Web of Science® Times Cited: 7

Wei Li, Anna Hellsten, Leif Jacobsson, Henrik Blomqvist, Anders Olsson and Xi Ming Yuan
  Alpha-tocopherol and astaxanthin decrease macrophage infiltration, apoptosis and vulnerability in atheroma of hyperlipidaemic rabbits
  Journal of Molecular and Cellular Cardiology, 2004, 37(5), 969-978.
 Web of Science® Times Cited: 31

Anders Olsson, A Jardine, H Holdaas, B Fellström, E Cole, G Nyberg, C Grönhagen-Riska, S Madsen, H-H Neumayer and B Maes
  Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: Post-hoc subgroup analyses of the ALERT study
  American Journal of Transplantation, 2004, 4(6), 988-995.
 Web of Science® Times Cited: 64

Gunilla Hollman, Anna-Christina Ek, Anders Olsson and Carina Berterö
  The meaning of quality of life among patients with familial hypercholesterolemia
  Journal of Cardiovascular Nursing, 2004, 19(4), 243-250.

Gunilla Hollman, Anna-Christina Ek and Anders Olsson
  Only one of four patients with familial hypercholesterolaemia reach cholesterol treatment goals in primary prevention
  Journal of Internal Medicine, 2004, 256(2), 176-177.
 Web of Science® Times Cited: 2

S Tsimikas, JL Witztum, ER Miller, WJ Sasiela, M Szarek, Anders Olsson and GG Schwartz
  High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial
  Circulation, 2004, 110(11), 1406-1412.
 Web of Science® Times Cited: 93

Ulf Stenestrand and Anders Olsson
  Ju lägre LDL-kolesterol destö bättre!
  Läkartidningen, 2004, 101, 3246-3247.

Anders Olsson
  Apolipoprotein A-I kan vara ettnytt verktyg i behandlingen av ateroskleros
  Läkartidningen, 2004, 101, 1196-1197.

Anders Olsson
  Replik: Att följa Ravnskovs råd skulle innebära återgång i ökad dödlighet och sjuklighet. Slutreplik
  Läkartidningen, 2004, 101, 1218-1222.

Anders Olsson
  Psychosocial factors and coronary heart disease
  Current Atherosclerosis Reports, 2004, 6(1), .

Anders Olsson
  Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in teh Scandinavian Simvastatin Survival Study
  Atherosclerosis, 2004, 5, 99-106.

Anders Olsson
  The importance of the emergence of statins toa lipidologist - clinician: a personal perspective
  Atherosclerosis, 2004, 5, 27-28.
 Web of Science® Times Cited: 1

S Lind, Anders Olsson, M Eriksson, M Rudling, G Eggertsen and B Angelin
  Autosomal recessive hypercholesterolaemia: Normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment
  Journal of Internal Medicine, 2004, 256(5), 406-412.
 Web of Science® Times Cited: 19

S Kinlay, G Schwartz, Anders Olsson, N Rifai, W Sasiela, M Szarek, P Ganz and P Libby
  Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study
  Circulation, 2004, 110(4), 386-391.
 Web of Science® Times Cited: 105

Lena Jonasson, A. Wikby and Anders Olsson
  Low serum ß-carotene reflects immune activation in patients with coronary artery disease
  NMCD. Nutrition Metabolism and Cardiovascular Diseases, 2003, 13(3), 120-125.
 Web of Science® Times Cited: 7

H. Holdaas, B. Fellstrom, A.G. Jardine, I. Holme, G. Nyberg, P. Fauchald, C. Gronhagen-Riska, S. Madsen, H.-H. Neumayer, E. Cole, B. Maes, P. Ambuhl, Anders Olsson, A. Hartmann, D.O. Solbu and T.R. Pedersen
  Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial
  The Lancet, 2003, 361(9374), 2024-2031.
 Web of Science® Times Cited: 429

Anders Olsson
  Vilka målvärden ska vi ha för lipidsänkande behandling?
  Information från Läkemedelsverket, 2003, 4, 37-42.

Anders Olsson
  Statins: how far have we come? A review of rosuvastatin.
  International journal of clinical practice (Esher), 2003, 137, 15-25.

S Kinlay, G Schwartz, Anders Olsson, N Rifai, S Leslie, WJ Sasiela, M Szarek, P Libby and P Ganz
  High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study
  Circulation, 2003, 108(13), 1560-1566.
 Web of Science® Times Cited: 228

Anders Olsson, M Eriksson, O Johnson, T Kjellström, J Lanke, M Lytken Larsen, T Pedersen, MJ Tikkanen and O Wiklund
  A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: The Treat-to-Target (3T) Study
  Clinical Therapeutics, 2003, 25(1), 119-138.
 Web of Science® Times Cited: 24

Gunilla Hollman, Anders Olsson and Anna-Christina Ek
  Familial hypercholesterolaemia and quality of life in family members
  Preventive Medicine, 2003, 36(5), 569-574.
 Web of Science® Times Cited: 9

Henrik Blomqvist and Anders Olsson
  Monocyte chemoattractant protein‐1 and CC‐chemokine receptor‐2 in severe hypercholesterolaemia
  Scandinavian Journal of Clinical and Laboratory Investigation, 2003, 63(7-8), 513-519.
 Web of Science® Times Cited: 4

Jane Wigren, Sailesh Surapureddi, Anders Olsson, C. K. Glass, Sven Hammarström and Mats Söderström
  Differential recruitment of the coactivator proteins CREB-binding protein and steroid receptor coactivator-1 to peroxisome proliferator-activated receptor gamma/9-cis-retinoic acid receptor heterodimers by ligands present in oxidized low-density lipoprotein
  Journal of Endocrinology, 2003, 177(2), 207-214.
 Web of Science® Times Cited: 12

C Packard and Anders Olsson
  Management of hypercholesterol - aemia in the patient with diabetes
  International journal of clinical practice (Esher), 2002, , 27-32.
 Web of Science® Times Cited: 2

B Zieden, A Kaminskas, M Kristenson, Anders Olsson and Z Kucinskiene
  Long chain polyunsaturated fatty acids may account for higher low-density lipoprotein oxidation susceptibility in Lithuanian compared to Swedish men
  Scandinavian Journal of Clinical and Laboratory Investigation, 2002, 62(4), 307-314.
 Web of Science® Times Cited: 9

Anders Olsson, F McTaggart and AG Raza
  Rosuvastatin: A highly effective new HMG-CoA reductase inhibitor
  Cardiovascular Drug Reviews, 2002, 20(4), 303-328.
 Web of Science® Times Cited: 71

Anders Olsson
  Rosuvastatin - A viewpoint by Anders G Olsson
  Drugs : international journal of current therapeutics and applied pharmacology reviews ..., 2002, 62, 2086-2086.

Anders Olsson
  Nya rön talar mot statinbehandling vid akut kranskärlssjukdom. Men vanskligt att bedöma behandlingseffekt utifrån observationella studier.
  Läkartidningen, 2002, 99, 4348-4349.

L Jonasson, C Linderfalk, J Olsson, A Wikby and Anders Olsson
  Systemic T-cell activation in stable angina pectoris
  American Journal of Cardiology, 2002, 89(6), 754-756.
 Web of Science® Times Cited: 15

Anders Olsson and GG Schwartz
  Early initiation of treatment with statins in acute coronary syndromes
  Annals of Medicine, 2002, 34(1), 37-41.
 Web of Science® Times Cited: 9

DD Waters, GG Schwartz, Anders Olsson, A Zeiher, MF Oliver, P Ganz, M Ezekowitz, BR Chaitman, SJ Leslie and T Stern
  Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: A myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) substudy
  Circulation, 2002, 106(13), 1690-1695.
 Web of Science® Times Cited: 119

Anders Olsson, Helge Istad, Olavi Luurila, Leiv Ose, Steen Stender, Jaakko Tuomilehto, Olov Wiklund, Harry Southworth, John Pears and J W Wilpshaar
  Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia
  American Heart Journal, 2002, 144(6), 1044-1051.
 Web of Science® Times Cited: 109

Anders Olsson, G G Schwartz, Lena Jonasson and C Linderfalk
  Are early clinical effects of cholesterol lowering mediated through effects on inflammation?
  Acta Physiologica Scandinavica, 2002, 176(2), 147-150.
 Web of Science® Times Cited: 16

GG Schwartz and Anders Olsson
  Lipid lowering in acute coronary syndromes: New evidence, new questions
  Current Atherosclerosis Reports, 2002, 4, .

Gunilla Hollman, Mats Gullberg, Anna-Christina Ek, Mats Eriksson and Anders G. Olsson
  Quality of life in patients with familial hypercholesterolaemia
  Journal of Internal Medicine, 2002, 251(4), 331-337.
 Web of Science® Times Cited: 14

Bertil Ekman, Torbjörn Lindström, Fredrik Nyström, Anders Olsson, Göran Toss and Hans Arnqvist
  A dose titration model for recombinant GH substitution aiming at normal plasma concentrations of IGF-I in hypopituitary adults
  European Journal of Endocrinology, 2002, 147(1), 49-57.
 Web of Science® Times Cited: 11

Anders Olsson
  A new statin: A new standard
  Clinical Cardiology, 2001, 24(8), 18-23.
 Web of Science® Times Cited: 4

Anders Olsson, J. Pears, J. McKellar, J. Mizan and A. Raza
  Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia
  American Journal of Cardiology, 2001, 88(5), 504-508.
 Web of Science® Times Cited: 140

Anders Olsson
  Statiner skall sättas in akut på sjukhus. Livsstilsrelaterade åtgärder vid kranskärlssjukdom får dock inte glömmas.
  Läkartidningen, 2001, 98, 2704-2706.

Anders Olsson
  Statin therapy and reductions in low-density lipoprotein cholesterol: Initial clinical data on the potent new statin rosuvastatin
  American Journal of Cardiology, 2001, 87(5 SUPPL. 1), .
 Web of Science® Times Cited: 33

D Waters, GG Schwartz and Anders Olsson
  The myocardial ischemia reduction with acute cholesterol lowering (MIRACL) trial: A new frontier for statins?
  Current Controlled Trials in Cardiovascular Medicine, 2001, 2(3), 111-114.
 Web of Science® Times Cited: 14

CM Ballantyne, Anders Olsson, TJ Cook, MF Mercuri, TR Pedersen and J Kjekshus
  Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S
  Circulation, 2001, 104(25), 3046-3051.
 Web of Science® Times Cited: 215

Anders Olsson
  A new statin: A new standard
  American Journal of Managed Care, 2001, 7, 152-154.
 Web of Science® Times Cited: 3

Gregory Schwartz, Anders Olsson, Michael Ezekowitz, Peter Ganz, Michael Oliver, David Waters, Andreas Zeither, Bernard Chaitman, Sally Leslie and Theresa Stern
  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial.
  Journal of the American Medical Association (JAMA), 2001, 285, 1711-1718.
 Web of Science® Times Cited: 1353

Hallvard Holdaas, Bengt Fellström, Ingar Holme, Gudrun Nyberg, Per Fauchald, Alan Jardine, Carola Grönhagen-Riska, Sören Madsen, Hans-Hellmut Neymayer, Edward Cole, Bart Meas, Weinreich Thomas, Anders Olsson, Terje Pedersen, Renée Benghozi and Anders Hartmann
  Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (assessment of Lescol in renal tranplantion) study design and baseline data
  Journal of Cardiovascular Risk, 2001, 8, 63-71.
 Web of Science® Times Cited: 58

Anders Olsson, P Pauciullo, V Soska, C Luley, RE Pieters, G Broda and B Palacios
  Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: A randomized trial
  Clinical Therapeutics, 2001, 23(1), 45-61.
 Web of Science® Times Cited: 15

L Ose, O Luurila, J Eriksson, Anders Olsson, H Lithell and B Widgren
  Cerivastatin gender effect: Sub-analyses of results from a multinational, randomised, double-blind study
  Current Medical Research and Opinion, 2000, 16(2), 80-87.
 Web of Science® Times Cited: 9

T.R. Pedersen, L. Wilhelmsen, O. Faergeman, T.E. Strandberg, G. Thorgeirsson, L. Troedsson, J. Kristianson, K. Berg, T.J. Cook, T. Haghfelt, J. Kjekshus, T. Miettinen, Anders Olsson, K. Pyorala and H. Wedel
  Follow-up study of patients randomized in The Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering
  American Journal of Cardiology, 2000, 86(3), 257-262.
 Web of Science® Times Cited: 164

Anders Olsson
  H÷gt kolesterolvΣrde diskrimineras i nya behandlingsrekommendationer
  Läkartidningen, 2000, 97(16), 1995-1996.

Anders Olsson
  Lipidprevention av kranskärlssjukdom utan sänkning av LDL-kolesterol.
  Läkartidningen, 2000, 97, 1368-1370.

Niels Erik Nielsen, Anders Olsson and Eva Swahn
  Plasma lipoprotein particle concentrations in postmenopausal women with unstable coronary artery disease: Analysis of diagnostic accuracy using receiver operating characteristics
  Journal of Internal Medicine, 2000, 247(1), 43-52.
 Web of Science® Times Cited: 7

Margareta Kristenson, Claes Lassvik, Björn Bergdahl, Z Kucinskiene, L Aizieniene, Bo Ziedén, Liselott Schäfer Elinder and Anders Olsson
  Ultrasound determined carotid and femoral atherosclerosis in Lithuanian and Swedish men: The LiVicordia study
  Atherosclerosis, 2000, 151(2), 501-508.
 Web of Science® Times Cited: 9

Anders Olsson
  Den nya kolesteroldebatten: Är lägst bäst?
  Läkartidningen, 1999, 96, 648-652.

Anders Olsson
  En ny sorts studie behövs.
  Läkartidningen, 1999, 96, 1949-1949.

J Mölgaard, S Wärjestam-Elf and Anders Olsson
  Efficacy and safety of simvastatin for highrisk hypercholseterolemia.
  American Journal of Cardiology, 1999, 83, 1043-1048.

Torbjörn Lindström, Fredrik Nyström, Anders Olsson, Hans Arnqvist and A-M Ottosson
  The lipoprotein profile differs during insulin treatment alone and combination therapy with insulin and sulphonylureas in patients with type2 diabetes mellitus.
  Diabetic Medicine, 1999, 16, 820-826.

Bo Zidén, A Kaminkas, Margareta Kristensson, Z Kucinskiene, B Vessby, Anders Olsson and U Diczfaluzy
  Increased plasma 7B-hydroxycholesterol concentrations in a population with high risk for cardiovascular disease.
  Arteriosclerosis, Thrombosis and Vascular Biology, 1999, 19, 967-971.

A Kaminskas, Bo Ziedén, B Elving, Margareta Kristenson, A Abaravicius, Björn Bergdahl, Anders Olsson and Z Kucinskiene
  Adipose tissue fatty acids in men from two populations with different cardiovascular risk - the LiVicordia study.
  Scandinavian Journal of Clinical and Laboratory Investigation, 1999, 59, 227-232.

Wei Li, Xi Ming Yuan, Anders Olsson and Ulf Brunk
  Uptake of Oxidized LDL by Macrophages Results in Partial Lysosomal Enzyme Inactivation and Relocation
  Arteriosclerosis, Thrombosis and Vascular Biology, 1998, 18(2), 177-84.

XiMing Yuan, Wei Li, Anders Olsson and Ulf Brunk
  The toxicity to macrophages of oxidized low-density lipoprotein is mediated through lysosomal damage
  Atherosclerosis, 1997, 133(2), 153-61.

Anders Olsson and XiMing Yuan
  Antioxidants in the prevention of atherosclerosis
  Current Opinion in Lipidology, 1996, 7(6), 374-80.

XiMing Yuan, Anders Olsson and Ulf Brunk
  Iron in human atheroma and LDL oxidation by macrophages following erythrophagocytosis
  Atherosclerosis, 1996, 124(1), 61-73.

XiMing Yuan, Ulf Brunk and Anders Olsson
  Effects of iron- and hemoglobin-loaded human monocyte-derived macrophages on oxidation and uptake of LDL
  Arteriosclerosis, Thrombosis and Vascular Biology, 1995, 15(9), 1345-51.

Leif S. Jacobsson, Karin Persson, Gunnar Aberg, Rolf G. G. Andersson, Bengt E. Karlberg and Anders G. Olsson
  Antiatherosclerotic Effects of the Angiotensin-Converting Enzyme Inhibitors Captopril and Fosinopril in Hypercholesterolemic Minipigs
  Journal of Cardiovascular Pharmacology, 1994, 24(4), 670-677.

Books

Anders Olsson
  Rosuvastatin in dyslipidaemia and coronary heart disease
  Science Press, 2004.


Chapters in Books

Margareta Kristenson, Z Kucinskiene, Björn Bergdahl, C Tagesson, K Orth-Gomer and Anders Olsson
  Self-rated health and biological mechanisms: experiences from the LiVicordia study.
  Self-rated health in a European perspective, Linköpings universitet, 2000, 167-175.


Conference Articles

Fabian Chen, Darbie Maccubbin, Jennifer Weimer Anderson, Christine McCrary Sisk, Uma Kher, Anders Olsson and Harold E Bays
  Following Stable Therapy with Extended Release Niacin/Laropiprant, Continued Extended Release Niacin/Laropiprant Use Reduced Flushing versus Extended Release Niacin Alone in Dyslipidemic Patients in CIRCULATION, vol 124, issue 21, pp
  CIRCULATION, 2011.


Matti J. Tikkanen, Rana Fayyad, Rachel Laskey, Ingar Holme, Ole Faergeman, Anders Olsson, Christina Lindahl, John J. Kastelein, Mogens Lytken Larsen and Terje R. Pedersen
  Among CHD Patients in the IDEAL Study, Those with Elevated Levels of Alanine Aminotransferase at Baseline Had a Lower Rate of Major Coronary Events in CIRCULATION, vol 124, issue 21, pp
  CIRCULATION, 2011.


R L Ohsfeldt, Anders Olsson, M M Jensen, S K Gandhi and T Paulsson
  The cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality - a swedish economic evaluation of the JUPITER trial in EUROPEAN HEART JOURNAL, vol 31, issue , pp 225-225
  EUROPEAN HEART JOURNAL, 2010.


Anders Olsson, C Lindahl, I Holme, R Fayyad, O Faergeman, J Kastelein, M Tikkanen, M Lytken Larsen and T Pedersen
  CORONARY PATIENTS REACHING LDL-CHOLESTEROL andlt; 2.0 mmol/L HAVE THE LOWEST RISK OF CARDIOVASCULAR EVENTS DURING STATIN TREATMENT: THE IDEAL STUDY in ATHEROSCLEROSIS SUPPLEMENTS, vol 11, issue 2, pp 53-53
  ATHEROSCLEROSIS SUPPLEMENTS, 2010.


Anders Olsson, C Lindahl, R Fayyad, S Bhatia and I Holme
  CAN LIPID/APOLIPOPROTEIN FACTORS ACCOUNT FOR RESIDUAL RISK IN PATIENTS ATTAINING CURRENT LDL-C TARGETS?
  ATHEROSCLEROSIS SUPPLEMENTS, 2009.


Johnny Nijm, Anders Olsson and Lena Jonasson
  Impaired cortisol response in patients with coronary artery disease - relation to inflammatory activity
  Scandinavian Cardiovascular Journal,2006, 2006.


Peter Garvin, Lena Jonasson, Margareta Kristenson, Johnny Nijm, Lennart Nilsson and Anders Olsson
  Psychosocial factors in atherosclerosis
  XIV International Symposium on Atherosclerosis,2006, 2006.


Johnny Nijm, Anders Olsson and Lena Jonasson
  Impaired cortisol response in patients with coronary artery disease - relation to inflammatory activity
  XIV International Symposium on Atherosclerosis,2006, 2006.


P Cherfan, Anders Olsson and Lena Jonasson
  Effects of simvastatin on human t-cells in vivo
  European Atherosclerosis Society Congress,2005, 2005.


Anders Olsson, P Cherfan, Henrik Blomqvist and Lena Jonasson
  Serum adiponectin - its association with inflammation and statin treatment
  EAS Congress,2005, 2005.


Gunilla Hollman, Anna-Christina Ek and Anders G. Olsson
  Achievement of treatment goals
  74th European Atherosclerosis Society (EAS) Congress, 17-20 April 2004, Seville, Spain, 2004.


Gunilla Hollman, Anders G. Olsson and Anna-Christina Ek
  The meaning of quality of life among patients with familial hypercholesterolaemia
  3rd Annual Spring Meeting Cardiovascular Nursing, 11-12 April 2003, Stockholm, Sweden, 2003.


Gunilla Hollman, Anna-Christina Ek and Anders G. Olsson
  Quality of life in family members in families with familial hypercholesterolemia
  Nordisk konferens om familjefokuserad omvårdnad, 2002, Kalmar, Sverige, 2002.


Anders Olsson and C Packard
  New global standards in lipid lowering: a review of emerging evidence and concepts.
  Int J Clin Practice,2002, 2002.


S Hellerström, M Malmgren, Anders Olsson, A Gustafsson and Göran Granerus
  Evaluation of radiation doses to medical staff working with 18 F-FDG gamma camera PET studies.
  World J Nucl Med,2002, 2002.


Gunilla Hollman, Anders Olsson and Anna-Christina Ek
  Quality of life in non affected family members of familial hypercholesterolemia families
  Konferens Familjefokuserad omvårdnad, Kalmar,2002, 2002.


O Nygard, H Refsum, J Kjekshus, PM Ueland, SE Vollset, K Berg, Anders Olsson, TJ Cook and TR Pedersen
  Total homocysteine levels predicts major coronary events and mortality in simvastatin treated patients of 4S
  Circulation, 2001.


D Waters, GG Schwartz, Anders Olsson, MF Oliver, P Ganz, MD Ezekowitz, S Leslie and T Stern
  Stroke reduction with atorvastatin in acute coronary syndromes: Results of the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) trial
  Circulation, 2001.


Gunilla Hollman, Anna-Christina Ek, Mats Eriksson and Anders Olsson
  Quality of life in familial hypercholesterolaemia families
  72nd European Atherosclerosis Society (EAS) Congress, 20-23 May 2001, Glasgow, UK, 2001.


Gunilla Hollman, Anna-Christina Ek, Mats Eriksson and Anders G. Olsson
  Quality of life in genetic disease: The example of familial hypercholesterolaemia
  Atherosclerosis XII, 2000.


Anders Olsson, JS Pears, J McKellar, RJ Caplan and A Raza
  ZD4522 - a new HMG-CoA reductase inhibitor - causes rapid and profound reductions in plasma LDL-C levels in patients with primary hypercholesterolaemia
  European Heart Journal, 2000.


L Jonasson, C Linderfalk, A Wikby and Anders Olsson
  T lymphocyte activation in stable angina pectoris: The influence of statin treatment.
  Circulation, 2000.


* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.